20679021-a108-4728-ab9a-fa3ca2fed0d0
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.300
- COAGULATION+0.200
- HEDGEHOG_SIGNALING+0.200
- TGF_BETA_SIGNALING+0.200
- WNT_BETA_CATENIN_SIGNALING+0.200
- APICAL_JUNCTION+0.100
- CHOLESTEROL_HOMEOSTASIS+0.100
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.100
- KRAS_SIGNALING_UP+0.100
- MYOGENESIS+0.100
Top 10 suppressed
- E2F_TARGETS-0.600
- G2M_CHECKPOINT-0.500
- ALLOGRAFT_REJECTION-0.400
- MITOTIC_SPINDLE-0.400
- INTERFERON_GAMMA_RESPONSE-0.300
- MYC_TARGETS_V2-0.300
- OXIDATIVE_PHOSPHORYLATION-0.300
- APICAL_SURFACE-0.200
- FATTY_ACID_METABOLISM-0.200
- HEME_METABOLISM-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-78-7161-01A-11R-2039-07 | — | cohortA3 | 0.803 |
| 2 | f4cfbfdb-3861-4731-92d8-74e66a7ae5a7 | — | — | 0.785 |
| 3 | 8d532c55-71b5-4992-9aba-7480d7c390ce | — | — | 0.767 |
| 4 | TCGA-MP-A4SY-01A-21R-A24X-07 | — | cohortA1 | 0.762 |
| 5 | SRR1313111 | — | A | 0.755 |
| 6 | C3L-02165 | — | cohortA2 | 0.750 |
| 7 | 432c57e1-e191-4fdc-9aaa-53e460c82acc | — | — | 0.749 |
| 8 | C3L-02834 | — | cohortA1 | 0.746 |
| 9 | C3N-02145 | — | cohortA1 | 0.746 |
| 10 | C3L-03463 | — | cohortA3 | 0.746 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.100 | Remibrutinib | — uncovered |